Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00604214
Registration number
NCT00604214
Ethics application status
Date submitted
24/01/2008
Date registered
30/01/2008
Date last updated
18/09/2012
Titles & IDs
Public title
Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock
Query!
Scientific title
A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of Drotrecogin Alfa (Activated) Administered as a Continuous 96-hr Infusion to Adult Patients With Septic Shock
Query!
Secondary ID [1]
0
0
F1K-MC-EVDP
Query!
Secondary ID [2]
0
0
11940
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Sepsis
0
0
Query!
Condition category
Condition code
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Drotrecogin alfa (activated)
Treatment: Drugs - Placebo
Experimental: Drotrecogin alfa (activated) -
Placebo comparator: Placebo -
Treatment: Drugs: Drotrecogin alfa (activated)
24 microgram/kilogram/hour, intravenous, 96 hours (hr)
Treatment: Drugs: Placebo
0.9% sodium chloride, intravenous, 96 hours
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
28-Day All-Cause Mortality
Query!
Assessment method [1]
0
0
Expressed as percentage of participants who died from any cause at Day 28 endpoint.
Query!
Timepoint [1]
0
0
Day 28
Query!
Secondary outcome [1]
0
0
28-Day All-Cause Mortality in Participants With Severe Protein C Deficiency
Query!
Assessment method [1]
0
0
Expressed as percentage of participants who died from any cause at Day 28 endpoint. Participants with severe protein C deficiency are those who had a protein C level = half the lower limit of normal (LLN) (=40%).
Query!
Timepoint [1]
0
0
Day 28
Query!
Secondary outcome [2]
0
0
Average Cardiovascular Sequential Organ Failure Assessment (SOFA) Score Day 1 Through Day 28
Query!
Assessment method [2]
0
0
Scores range from 0 (normal) to 4 (organ failure) with an increasing score indicating increasing cardiovascular dysfunction. A non-surviving participant receives a score of 4 (worst score) for the day of death and every day thereafter.
Query!
Timepoint [2]
0
0
Day 1 through Day 28
Query!
Secondary outcome [3]
0
0
Average Respiratory Sequential Organ Failure Assessment (SOFA) Score Day 1 Through Day 28
Query!
Assessment method [3]
0
0
Scores range from 0 (normal) to 4 (organ failure) with an increasing score indicating increasing respiratory dysfunction. A non-surviving participant receives a score of 4 (worst score) for the day of death and every day thereafter.
Query!
Timepoint [3]
0
0
Day 1 through Day 28
Query!
Secondary outcome [4]
0
0
Average Renal Sequential Organ Failure Assessment (SOFA) Score Day 1 Through Day 28
Query!
Assessment method [4]
0
0
Scores range from 0 (normal) to 4 (organ failure) with an increasing score indicating increasing renal dysfunction. A non-surviving participant receives a score of 4 (worst score) for the day of death and every day thereafter.
Query!
Timepoint [4]
0
0
Day 1 through Day 28
Query!
Secondary outcome [5]
0
0
90-Day Mortality
Query!
Assessment method [5]
0
0
Expressed as percentage of participants who died from any cause at Day 90 endpoint.
Query!
Timepoint [5]
0
0
Day 90
Query!
Secondary outcome [6]
0
0
180-Day Mortality
Query!
Assessment method [6]
0
0
Expressed as percentage of participants who died from any cause at Day 180 endpoint.
Query!
Timepoint [6]
0
0
Day 180
Query!
Secondary outcome [7]
0
0
Median Survival Time
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Day 180
Query!
Secondary outcome [8]
0
0
EuroQoL Questionnaire-5 Dimensions (EQ-5D) Visual Analog Scale (VAS) Scores at Baseline, Days 28, 90 and 180
Query!
Assessment method [8]
0
0
EQ-5D VAS assesses caregiver's impression of participant's overall health state. Scores range from 0 (worst health state) to 100 (best health state), with higher scores indicating a better health state.
Query!
Timepoint [8]
0
0
Baseline and Days 28 and 90 and 180
Query!
Secondary outcome [9]
0
0
EuroQoL Questionnaire-5 Dimensions (EQ-5D) Total Scores at Baseline, Days 28, 90 and 180
Query!
Assessment method [9]
0
0
The EQ-5D is used to assess participant's overall health. Consists of 5 items: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each item has 3 severity levels (no, some, severe problems). Calculated from EQ-5D, total scores (United States \[US\] Index Score) range from 0 (worst quality of life) to 1.00 (best quality of life).
Query!
Timepoint [9]
0
0
Baseline and Days 28 and 90 and 180
Query!
Secondary outcome [10]
0
0
Quality of Life Short Form-12 (SF-12) Scores at Baseline, Days 28, 90 and 180
Query!
Assessment method [10]
0
0
SF-12 was used as an instrument to measure participants' physical wellbeing (physical component) and mental wellbeing (mental component). Scores for each component range from 0-100, with 0= lowest wellbeing, and 100=highest wellbeing.
Query!
Timepoint [10]
0
0
Baseline and Days 28 and 90 and 180
Query!
Secondary outcome [11]
0
0
Percentage of Participants Discontinued Due to Adverse Events Any Time From Baseline Through Day 28 Endpoint
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
Baseline through Day 28
Query!
Eligibility
Key inclusion criteria
* Must be 18 years or older
* Must have evidence of infection
* Must have systemic inflammatory response syndrome (SIRS)
* Must have vasopressor-dependent septic shock
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Have received vasopressor therapy (at any dose) for greater than 24 hours prior to the start of study drug
* Have sepsis-induced organ dysfunction for greater than 36 hours prior to the start of the study drug infusion
* Have single organ dysfunction and recent surgery (within 30 days of study entry)
* Have had surgery performed within the 12-hour period immediately preceding the study drug infusion, or are postoperative with evidence of active bleeding, or have planned or anticipated surgery during the infusion period
* Are not expected to survive 28 days given their preexisting uncorrectable medical condition
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/03/2008
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/02/2012
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1696
Query!
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Garran
Query!
Recruitment hospital [2]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Newcastle
Query!
Recruitment hospital [3]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - St. Leonards
Query!
Recruitment hospital [4]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Herston
Query!
Recruitment hospital [5]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Adelaide
Query!
Recruitment hospital [6]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Box Hill
Query!
Recruitment hospital [7]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Epping
Query!
Recruitment hospital [8]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Heidelberg
Query!
Recruitment hospital [9]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Melbourne
Query!
Recruitment hospital [10]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Parkville
Query!
Recruitment postcode(s) [1]
0
0
2605 - Garran
Query!
Recruitment postcode(s) [2]
0
0
2305 - Newcastle
Query!
Recruitment postcode(s) [3]
0
0
2065 - St. Leonards
Query!
Recruitment postcode(s) [4]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [5]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [6]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [7]
0
0
3076 - Epping
Query!
Recruitment postcode(s) [8]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [9]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [10]
0
0
3050 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Idaho
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Iowa
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kansas
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kentucky
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Michigan
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Missouri
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Montana
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New York
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
North Carolina
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Oregon
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Pennsylvania
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Texas
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Virginia
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Antwerpen
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Antwerp
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Brussels
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Edegem
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Genk
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Leuven
Query!
Country [24]
0
0
Belgium
Query!
State/province [24]
0
0
Liège
Query!
Country [25]
0
0
Belgium
Query!
State/province [25]
0
0
Ottignies
Query!
Country [26]
0
0
Belgium
Query!
State/province [26]
0
0
Roeselare
Query!
Country [27]
0
0
Belgium
Query!
State/province [27]
0
0
Wilrijk
Query!
Country [28]
0
0
Belgium
Query!
State/province [28]
0
0
Yvoir
Query!
Country [29]
0
0
Brazil
Query!
State/province [29]
0
0
Belo Horizonte
Query!
Country [30]
0
0
Brazil
Query!
State/province [30]
0
0
Joinville
Query!
Country [31]
0
0
Brazil
Query!
State/province [31]
0
0
Londrina
Query!
Country [32]
0
0
Brazil
Query!
State/province [32]
0
0
Porto Alegre
Query!
Country [33]
0
0
Brazil
Query!
State/province [33]
0
0
Sao Jose Rio Preto
Query!
Country [34]
0
0
Brazil
Query!
State/province [34]
0
0
São Paulo
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Alberta
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
British Columbia
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
Manitoba
Query!
Country [38]
0
0
Canada
Query!
State/province [38]
0
0
Ontario
Query!
Country [39]
0
0
Canada
Query!
State/province [39]
0
0
Quebec
Query!
Country [40]
0
0
Czech Republic
Query!
State/province [40]
0
0
Brno
Query!
Country [41]
0
0
Czech Republic
Query!
State/province [41]
0
0
Hradec Kralove
Query!
Country [42]
0
0
Czech Republic
Query!
State/province [42]
0
0
Olomouc
Query!
Country [43]
0
0
Czech Republic
Query!
State/province [43]
0
0
Plzen
Query!
Country [44]
0
0
Czech Republic
Query!
State/province [44]
0
0
Prague
Query!
Country [45]
0
0
Czech Republic
Query!
State/province [45]
0
0
Usti Nad Labem
Query!
Country [46]
0
0
Finland
Query!
State/province [46]
0
0
Helsinki
Query!
Country [47]
0
0
Finland
Query!
State/province [47]
0
0
Jyvaskyla
Query!
Country [48]
0
0
Finland
Query!
State/province [48]
0
0
Kuopio
Query!
Country [49]
0
0
Finland
Query!
State/province [49]
0
0
Lahti
Query!
Country [50]
0
0
Finland
Query!
State/province [50]
0
0
Seinajoki
Query!
Country [51]
0
0
Finland
Query!
State/province [51]
0
0
Tampere
Query!
Country [52]
0
0
France
Query!
State/province [52]
0
0
Angers
Query!
Country [53]
0
0
France
Query!
State/province [53]
0
0
Argenteuil
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Bobigny
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
Bordeaux
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
Dijon
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
La Roche Sur Yon
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Le Kremlin Bicetre
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Limoges
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
Lyon
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
Montpellier
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Nantes
Query!
Country [63]
0
0
France
Query!
State/province [63]
0
0
Nice
Query!
Country [64]
0
0
France
Query!
State/province [64]
0
0
Nimes
Query!
Country [65]
0
0
France
Query!
State/province [65]
0
0
Paris
Query!
Country [66]
0
0
France
Query!
State/province [66]
0
0
Poissy
Query!
Country [67]
0
0
France
Query!
State/province [67]
0
0
Poitiers
Query!
Country [68]
0
0
France
Query!
State/province [68]
0
0
Pringy
Query!
Country [69]
0
0
France
Query!
State/province [69]
0
0
Rennes
Query!
Country [70]
0
0
France
Query!
State/province [70]
0
0
Saint Michel
Query!
Country [71]
0
0
France
Query!
State/province [71]
0
0
Saint-Etienne
Query!
Country [72]
0
0
France
Query!
State/province [72]
0
0
Toulon
Query!
Country [73]
0
0
France
Query!
State/province [73]
0
0
Tours
Query!
Country [74]
0
0
France
Query!
State/province [74]
0
0
Vandoeuvre-Les-Nancy
Query!
Country [75]
0
0
Germany
Query!
State/province [75]
0
0
Aachen
Query!
Country [76]
0
0
Germany
Query!
State/province [76]
0
0
Augsburg
Query!
Country [77]
0
0
Germany
Query!
State/province [77]
0
0
Berlin
Query!
Country [78]
0
0
Germany
Query!
State/province [78]
0
0
Gottingen
Query!
Country [79]
0
0
Germany
Query!
State/province [79]
0
0
Hamburg
Query!
Country [80]
0
0
Germany
Query!
State/province [80]
0
0
Heidelberg
Query!
Country [81]
0
0
Germany
Query!
State/province [81]
0
0
Kiel
Query!
Country [82]
0
0
Germany
Query!
State/province [82]
0
0
Munich
Query!
Country [83]
0
0
India
Query!
State/province [83]
0
0
Bangalore
Query!
Country [84]
0
0
India
Query!
State/province [84]
0
0
New Delhi
Query!
Country [85]
0
0
India
Query!
State/province [85]
0
0
Pune
Query!
Country [86]
0
0
Italy
Query!
State/province [86]
0
0
Catania
Query!
Country [87]
0
0
Italy
Query!
State/province [87]
0
0
Firenze
Query!
Country [88]
0
0
Italy
Query!
State/province [88]
0
0
Milano
Query!
Country [89]
0
0
Italy
Query!
State/province [89]
0
0
Monza
Query!
Country [90]
0
0
Italy
Query!
State/province [90]
0
0
Novara
Query!
Country [91]
0
0
Italy
Query!
State/province [91]
0
0
Padova
Query!
Country [92]
0
0
Italy
Query!
State/province [92]
0
0
Rome
Query!
Country [93]
0
0
Italy
Query!
State/province [93]
0
0
Torino
Query!
Country [94]
0
0
Italy
Query!
State/province [94]
0
0
Varese
Query!
Country [95]
0
0
Mexico
Query!
State/province [95]
0
0
Mexico City
Query!
Country [96]
0
0
Mexico
Query!
State/province [96]
0
0
Tlalpan
Query!
Country [97]
0
0
Netherlands
Query!
State/province [97]
0
0
Arnhem
Query!
Country [98]
0
0
Netherlands
Query!
State/province [98]
0
0
Ede
Query!
Country [99]
0
0
Netherlands
Query!
State/province [99]
0
0
Nijmegen
Query!
Country [100]
0
0
New Zealand
Query!
State/province [100]
0
0
Auckland
Query!
Country [101]
0
0
New Zealand
Query!
State/province [101]
0
0
Christchurch
Query!
Country [102]
0
0
New Zealand
Query!
State/province [102]
0
0
Grafton
Query!
Country [103]
0
0
New Zealand
Query!
State/province [103]
0
0
Hamilton
Query!
Country [104]
0
0
New Zealand
Query!
State/province [104]
0
0
Wellington
Query!
Country [105]
0
0
Portugal
Query!
State/province [105]
0
0
Lisbon
Query!
Country [106]
0
0
Portugal
Query!
State/province [106]
0
0
Porto
Query!
Country [107]
0
0
Spain
Query!
State/province [107]
0
0
Alcala De Henares
Query!
Country [108]
0
0
Spain
Query!
State/province [108]
0
0
Barcelona
Query!
Country [109]
0
0
Spain
Query!
State/province [109]
0
0
Burgos
Query!
Country [110]
0
0
Spain
Query!
State/province [110]
0
0
Getafe
Query!
Country [111]
0
0
Spain
Query!
State/province [111]
0
0
Las Palmas
Query!
Country [112]
0
0
Spain
Query!
State/province [112]
0
0
Madrid
Query!
Country [113]
0
0
Spain
Query!
State/province [113]
0
0
Murcia
Query!
Country [114]
0
0
Spain
Query!
State/province [114]
0
0
Palma De Mallorca
Query!
Country [115]
0
0
Spain
Query!
State/province [115]
0
0
Sabadell
Query!
Country [116]
0
0
Spain
Query!
State/province [116]
0
0
Sevilla
Query!
Country [117]
0
0
Spain
Query!
State/province [117]
0
0
Tortosa
Query!
Country [118]
0
0
Spain
Query!
State/province [118]
0
0
Valladolid
Query!
Country [119]
0
0
Switzerland
Query!
State/province [119]
0
0
Lugano
Query!
Country [120]
0
0
Switzerland
Query!
State/province [120]
0
0
St Gallen
Query!
Country [121]
0
0
Switzerland
Query!
State/province [121]
0
0
Zurich
Query!
Country [122]
0
0
United Kingdom
Query!
State/province [122]
0
0
Avon
Query!
Country [123]
0
0
United Kingdom
Query!
State/province [123]
0
0
Devon
Query!
Country [124]
0
0
United Kingdom
Query!
State/province [124]
0
0
Essex
Query!
Country [125]
0
0
United Kingdom
Query!
State/province [125]
0
0
Hampshire
Query!
Country [126]
0
0
United Kingdom
Query!
State/province [126]
0
0
Hants
Query!
Country [127]
0
0
United Kingdom
Query!
State/province [127]
0
0
Scotland
Query!
Country [128]
0
0
United Kingdom
Query!
State/province [128]
0
0
Surrey
Query!
Country [129]
0
0
United Kingdom
Query!
State/province [129]
0
0
West Midlands
Query!
Country [130]
0
0
United Kingdom
Query!
State/province [130]
0
0
West Sussex
Query!
Country [131]
0
0
United Kingdom
Query!
State/province [131]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Eli Lilly and Company
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this placebo-controlled study is to determine if drotrecogin alfa (activated) treatment provides significant mortality reduction improvement in patients with septic shock compared with placebo treatment in patients receiving the current standard of care for septic shock. This study will also assess the effectiveness of drotrecogin alfa (activated) in reducing 28-day mortality in patients with septic shock and concomitant severe protein C deficiency.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00604214
Query!
Trial related presentations / publications
Povoa P, Salluh JI, Martinez ML, Guillamat-Prats R, Gallup D, Al-Khalidi HR, Thompson BT, Ranieri VM, Artigas A. Clinical impact of stress dose steroids in patients with septic shock: insights from the PROWESS-Shock trial. Crit Care. 2015 Apr 28;19(1):193. doi: 10.1186/s13054-015-0921-x. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gardlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD; PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012 May 31;366(22):2055-64. doi: 10.1056/NEJMoa1202290. Epub 2012 May 22.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Query!
Address
0
0
Eli Lilly and Company
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT00604214
Download to PDF